BD Board Declares Dividend
The Board of Directors of Becton, Dickinson and Company (NYSE: BDX) has declared a quarterly dividend of $0.91 per common share, scheduled for payment on March 31, 2023.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
The Board of Directors of Becton, Dickinson and Company (NYSE: BDX) has declared a quarterly dividend of $0.91 per common share, scheduled for payment on March 31, 2023. This will benefit shareholders on record as of March 10, 2023, translating to an indicated annual dividend rate of $3.64 per share. BD remains a leader in global medical technology, focusing on enhancing health through improved medical discovery and diagnostics, serving healthcare providers worldwide.
Positive
- Quarterly dividend of $0.91 per share reflects strong cash flow and commitment to shareholders.
- Indicated annual dividend rate of $3.64 indicates company confidence in sustainable financial performance.
Negative
- None.
Details
News Market Reaction – BDX
The recorded move for BDX in the trading session of this news was +0.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and
Contacts: | |
Media: | Investors: |
Troy Kirkpatrick | |
VP, Public Relations | SVP, Head of Investor Relations |
858.617.2361 | 201.847.5743 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-board-declares-dividend-301729465.html
SOURCE BD (
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.